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Abstract 35 
Background: There is a pressing need for blood pressure control strategies with improved efficacy and 36 
tolerability. We examine whether using ultra-low dose quadruple combination therapy provides an 37 
approach with greater efficacy and tolerability.  38 
Methods: We conducted a systematic review of trials evaluating the efficacy and safety of quarter-39 
standard dose BP-lowering therapy against placebo and a randomised, placebo-controlled, double-blind, 40 
cross-over trial of a ‘quadpill’: a single capsule containing four BP-lowering medicines each at quarter-41 
dose (irbesartan 37.5mg, amlodipine 1.25mg, hydrochlorothiazide 6.25mg and atenolol 12.5mg). 42 
Participants with untreated hypertension received either quadpill or matching placebo for four weeks, 43 
followed by a two-week wash-out and then the other treatment for four weeks. The primary outcome 44 
was placebo-corrected 24-hour systolic ambulatory BP reduction after four weeks.  45 
Findings: Our systematic review identified 36 trials (n=4,721) of single quarter-dose and six trials (n=312) 46 
of dual quarter-dose therapy against placebo. The pooled placebo-corrected BP-lowering effects were 47 
5/2mmHg and 7/5mmHg (both p<0.0001) respectively, and there were no side effects from either 48 
regimen. The trial is complete and stopped recruiting due to inadequate funding. It randomised 20 49 
patients, whose mean age was 60 years and mean baseline office and 24-hour systolic BP levels were 50 
154/90 and 138/87mmHg, respectively. Two patients dropped out for administrative reasons.  The 51 
placebo-corrected reduction in systolic 24-hour BP on quadpill was 19mmHg (95%CI 14-23) and office BP 52 
was reduced by 22/13mmHg (p<0.001). During quadpill treatment 18/18 (100%) achieved office 53 
BP<140/90mmHg, compared to 6/18 (33%) during placebo treatment (p=0.0013). There were no serious 54 
adverse events and all patients reported that the quadpill was easy to swallow.  55 
Interpretation: This small trial in the context of previous randomised evidence indicates that the 56 
benefits of quarter-dose therapy are additive across classes, and are likely to confer a clinically 57 
important BP reduction. Further examination of the quadpill concept is needed to examine effectiveness 58 
against usual treatment options and longer term tolerability. 59 
Funding: National Heart Foundation, Australia (Grant number 100227), University of Sydney Bridging 60 
Grant and National Health and Medical Research Council of Australia program grant.  61 
 62 
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  64 
INTRODUCTION 65 
High blood pressure (BP) is a leading cause of preventable morbidity and mortality,1 and the benefits of 66 
BP lowering treatments are well established.2,3  Despite the plethora of BP lowering medicines available 67 
and the fact that most patients receive some treatment, multiple large-scale population studies 68 
demonstrate poor BP control in many patients globally.4 69 
Multiple factors contribute to poor BP control including low adherence rates, complex guidelines 70 
recommending multiple up-titration steps and treatment inertia. The majority of treated patients only 71 
receive monotherapy,4 which has low potency even at high doses.5 Furthermore the increasingly strong 72 
evidence of benefits of more intensive BP lowering6,7 highlights the need for new treatment strategies 73 
that are more efficacious, while remaining tolerable. Low-dose combination therapy holds considerable 74 
promise in this regard, since at low doses most side effects are avoided and most benefits are 75 
maintained.8   76 
However, there is uncertainty about effects at ultra-low doses and whether combinations can achieve 77 
clinically relevant BP reductions. We therefore sought to assess efficacy and tolerability of ultra-low 78 
dose combination therapy by conducting a systematic review of quarter-dose BP lowering therapies and 79 
a trial of a ‘quadpill’, containing four common BP lowering medications each at quarter-dose.  80 
METHODS 81 
Systematic review 82 
We conducted a systematic review of all randomised trials of quarter-dose BP therapy, identifying 83 
potentially relevant studies from searches of EMBASE, MEDLINE and Cochrane Central Registry of 84 
Controlled Trials, with each source searched from inception to June 2016; and the Food and Drug 85 
Administration and European Medicines Agency websites. Medline search terms are in appendix 1.   86 
Searches of trial registers were performed for any ongoing trials including World Health Organization 87 
International Clinical Trials Registry Platform (WHO-ICTRP), Australia New Zealand Clinical Trial Register 88 
(ANZCTR) and Clinical Trials Registry – India (CTRI). Retrieval of studies from reference lists of key clinical 89 
trials, systematic reviews and published articles was also undertaken. Reference lists of eligible studies 90 
and systematic reviews were also reviewed. (Appendix Figure 1) We included randomised controlled 91 
trials of adult participants (≥18 years of age) examining quarter-standard dose BP-lowering drugs against 92 
placebo for the following drug classes: angiotensin converting enzyme inhibitors, angiotensin receptor II 93 
blockers, beta-blockers, calcium channel blockers and thiazide and thiazide-like diuretics. Quarter dose 94 
was quarter of the standard dose, defined as the most frequently reported usual maintenance dose 95 
recorded by the British National Formulary,9 Martindales and Monthly Index of Medical Specialties.10 96 
Two reviewers (AB, MC) independently extracted data using a standard extraction form.  A third 97 
reviewer (AR) resolved any differences.  Data were analysed using Comprehensive Meta-analysis 98 
Software (v3, Englewood NJ). We a fixed-effect model to estimate the effects on BP lowering and on 99 
adverse events of quarter dose BP lowering against placebo. Effect on BP was assessed using the mean 100 
change in systolic BP (SBP) and diastolic BP (DBP) from baseline to end-of-study, with standardisation to 101 
a baseline of 150/95mmHg.8 Adverse events included all that were reported by trials at follow up.  102 
Clinical trial 103 
Design and participants 104 
The Quadpill study was a randomised, placebo-controlled, double-blind cross-over trial (Figure 1). 105 
Participants were randomised (1:1) to a group receiving the quadpill for four weeks, followed by a two-106 
week placebo washout and then placebo for four weeks; or to a group receiving placebo, then washout, 107 
then Quadpill for the same periods. Participants were recruited from the community, predominantly 108 
through general practices in Western Sydney, Australia. Participants were eligible if they met the 109 
following inclusion criteria: 1) adults aged 18 years and over; 2) office SBP>140mmHg and/or DBP> 110 
90mmHg on two readings on separate days; 3) baseline ambulatory SBP >135mmHg and/or DBP 111 
>85mmHg; and 4) not taking any BP medications. Exclusion criteria included: 1) definite contraindication 112 
to one or more component medications in the quadpill; 2) the responsible clinician considered that a 113 
change in current therapy would place the patient at risk; 3) severe or accelerated hypertension; 4) 114 
pregnancy; 5) inability to provide informed consent; and 6) medical illness with anticipated life 115 
expectancy less than 3 months. The study protocol was approved by the Human Research and Ethics 116 
committee at The University of Sydney and funded by a Vanguard Grant and Ross Hohnen prize from the 117 
National Heart Foundation of Australia (Grant number 100227), University of Sydney Bridging Grant and 118 
National Health and Medical Research Council of Australia program grant. Informed consent was 119 
obtained from all participants. The study is registered with the Australian and New-Zealand Clinical Trials 120 
Registry (ACTRN 12614001057673).  121 
Intervention and randomisation 122 
The quadpill was a single encapsulated pill containing four common BP lowering medicines each at 123 
quarter-standard dose (irbesartan 37.5mg, amlodipine 1.25mg, hydrochlorothiazide 6.25mg and 124 
atenolol 12.5mg). Quarter- doses were obtained by halving half- doses using a pill splitting device, 125 
without crushing, and were weighed to ensure accuracy of halving doses. The quarter doses were then 126 
encapsulated using gelatine capsules (DBCaps- Capsugel).11 All trial medicines were prepared and 127 
packaged at a Therapeutic Goods Australia – Certificate of Good Manufacturing Practice licensed 128 
manufacturing facility. 129 
Treatment allocations were at random via a computer assisted randomisation sequence and were 130 
blinded to both study staff and participants.  The placebo capsule appeared identical and contained four 131 
placebo tablets of similar weight to those in the quadpill. Participants were administered a single daily 132 
capsule quadpill or placebo throughout the trial. Patients were instructed to take the capsules at the 133 
same time each day, preferably in the morning. In addition to the study drugs, all participants were 134 
provided education on healthy lifestyle options as recommended by then current local BP management 135 
guidelines.12  136 
Outcomes and data collection 137 
The primary outcome was reduction in mean 24-hour SBP at 4 weeks using ambulatory BP monitoring 138 
(ABP). The secondary outcomes included:  139 
1) Reduction in mean 24-hour DBP and in daytime and night-time SBP and DBP at 4 weeks 140 
2) Reduction in office SBP and DBP as measured by a standardised automated BP cuff 141 
3) Proportion with controlled BP at 4 weeks, defined as <135/85mmHg 24-hour ABP and 142 
<140/90mmHg office BP 143 
4) Adverse events and pre-specified adverse events with laboratory-associated parameters: rise in 144 
transaminases (ALT/AST) more than three times the upper limit of normal or doubling if baseline 145 
levels known to be elevated; drop in estimated glomerular filtration rate by >20% as estimated from 146 
serum creatinine; change in sodium, potassium and uric acid levels  147 
5) Assessment of acceptability and tolerability 148 
Patients underwent 24-hour ABP monitoring 4 times - baseline (off study drug), 4 weeks (on phase 1 149 
treatment or placebo), 6 weeks (after 2 week placebo washout) and 10 weeks (on phase 3 treatment or 150 
placebo). The ABP units were calibrated at regular intervals by the laboratory according to the 151 
manufacturer’s specification. Office BP was recorded three times at each visit using an OMRON T9P 152 
(HEM-759-C1). The second and the third readings were averaged for study analysis. In addition, at week 153 
4 and week 10 blood biochemistry and a questionnaire for clinical side effects and medication 154 
compliance were administered. At study end, drug acceptability and tolerability were assessed. We 155 
recorded all adverse events. In addition, we specifically asked about clinical adverse events possibly 156 
associated with BP lowering medications: dizziness, blurred vision, syncope/collapse, chest pain/angina, 157 
shortness of breath, cough, wheeze, pedal oedema, skin rash, or itching. Study medications and 158 
investigations were provided at no cost to participants and nominal amounts to cover travel and parking 159 
costs were reimbursed.   160 
Statistical considerations:  161 
A sample size of 50 patients was planned to provide 90% power at α =0.05 to detect a SBP difference of 162 
12mmHg between the intervention and control, assuming a SD of the within patient difference of 163 
12mmHg and taking into account the possibility of a 10% loss to follow-up. The study ended at one year 164 
at the end of the budget and staffing time allocated and the original sample size was not reached.  165 
Analyses were conducted on an intention to treat basis.  All tests were two-sided. All statistical analyses 166 
were unadjusted for prognostic covariates. We reported compliance to the study drug using data on pills 167 
(doses) taken and missed doses over the time period. We used a linear mixed model to estimate the 168 
effect of the treatment on change in BP from baseline for each treatment period, according to the 169 
Kenward and Roger approach.13 All available data were included in the model; no missing data were 170 
imputed. If a patient had missing data for one period, data from the available period were used. A 171 
sensitivity analysis was done including only patients with data available from both periods to see if the 172 
effect of treatment was modified. We also adjusted the denominator degrees of freedom of Kenward 173 
and Roger (2009)14 to optimize for the small sample size. 174 
We tested for carry over with an unpaired t-test of the main outcome with order as an effect. Period 175 
effect was tested by using a paired t-test comparing the main outcome in period 1 with main outcome in 176 
period 2 from the same patient. We also performed a sensitivity analysis using normal paired t-test to 177 
compare primary outcome between different period (different treatment) from the same patient, 178 
ignoring the baseline level of each period. 179 
Continuous secondary endpoints with baseline values (e.g. daytime/ night-time ambulatory SBP/DBP) 180 
were analysed similarly to the primary endpoint. Other continuous variables without a baseline value in 181 
each period were analysed with a paired t-test.  We have reported counts and percentages of all 182 
adverse events.  183 
We tested for interaction of treatment effect with age (≤60 vs. >60 years), gender, and body mass index 184 
(BMI ≤30 vs. >30 kg/m2). We also carried out subgroup analyses for each variable. Trial analyses were 185 
conducted using SAS 9.4 (Cary, NC, USA) software.  186 
Role of funders: The funder had no direct involvement in any of the following: data collection, analysis, 187 
interpretation, writing of the manuscript and the decision to submit. K Vo and K Rodgers conducted the 188 
statistical analysis for this paper and together with C Chow and A Rodgers had full access to the data. CC 189 
and AR were responsible for the decision to submit the manuscript.  190 
 191 
Results 192 
In the systematic review we identified 36 trials (4,721 participants)  that reported the efficacy of single 193 
quarter dose BP lowering compared to placebo. (Appendix table 1) Pooling the data, quarter dose BP-194 
lowering drugs reduced SBP by 4.7mmHg (95% CI -5.4 to -3.9) and DBP by 2.4mmHg (95% CI -2.8 to -195 
1.9). (Figure 2)  Further 14 of these trials (n=1,838) reported adverse events in single quarter dose 196 
versus placebo. Overall single quarter-dose agents had no increase in adverse events compared to 197 
placebo (Risk Ratio [RR] 1.0, 95% CI 0.88 – 1.10). Six trials (n=312) also examined dual quarter dose 198 
against placebo and found a reduction in SBP and DBP of 6.7mmHg (95% CI -4.8 to -8.6) and 4.4mmHg 199 
(95% CI -3.3 to -5.5) respectively and no increase in side effects compared to placebo (RR 0.93, 95% CI 200 
0.29 – 2.9). No trials of triple or quadruple quarter dose therapy versus placebo were identified.  201 
In the quadpill trial, 55 patients were screened, and 21 participants found eligible, one patient declined 202 
prior to drug initiation. Twenty were randomised between November 2014 and December 2015 and two 203 
withdrew at the end of the first treatment period because of social reasons (Figure 3). Baseline 204 
characteristics of the study population are shown in Table 1.  205 
The difference in mean 24-hour SBP between quadpill and placebo periods was –18.7mmHg (95% CI -206 
23.0 to -14.3) and 24-hour DBP was –14.2mmHg (94% CI -16.9 to -11.5). Similarly the difference in office 207 
SBP was -22.4mmHg (95% CI 16.5 to 28.3) and office DBP –13.1mmHg (95% CI 8.9 to 17.3). Daytime 208 
ASBP, daytime ADBP, night-time ASBP and night-time ADBP were all significantly lower with quadpill 209 
(Table 2). All participants achieved an office SBP <140 and DBP<90mmHg on the quadpill compared to 210 
6/18 (33%) while on placebo (RR 3.01, 95% CI 1.54; 5.89; p=0.0013). ABP<135/85mmHgwas achieved by 211 
15/18 (83%) while on the quadpill compared to 7/18 (39%) while on placebo, (RR 2.14, 95% CI 1.25-3.65; 212 
p=0.0053) 213 
 214 
Tests for both a carryover effect (t=-0.17, p=0.868) and a period effect (t=-1.05, p=0.308) were not 215 
significant. There were no significant interactions by age, sex or BMI. In sensitivity analysis using a 216 
standard comparison (paired t-test), results were virtually identical with a difference in mean 24-hour 217 
SBP between the quadpill and placebo periods of -18.7mmHg (95% CI -23.1 to -14.2). Similarly, in a 218 
second sensitivity analysis that included only patients with complete data (n=18) from both periods, 219 
results were also virtually identical with the difference in mean 24-hour SBP of -18.7 (95% CI -23.2 to -220 
14.2).  221 
Treatment compliance was high with the mean number of capsules missed in the last week 0.2 (SD 0.4) 222 
for quadpill and 0.3 (SD 0.6) for placebo. All 18 participants who finished the study completed the end-223 
of-study acceptability questionnaire, with all reporting the study medication was either very easy (n=13) 224 
or easy (n=5) to swallow. In addition, all 18 participants reported it was either very likely (n=10) or likely 225 
(n=8) they would take the quadpill if available for use. 226 
There were no serious adverse events and no patients had a pre-specified adverse events. One 227 
participant reported dizziness while on the quadpill causing temporary discontinuation of treatment; 228 
one reported vertigo during the washout period on placebo; and one reported urinary frequency in 229 
quadpill and placebo phases (see Table 3).  230 
The mean heart rate was lower on Quadpill treatment, difference between groups of 6.5 beats per 231 
minute (95% CI 2.3 to 10.6). There was a difference in changes in creatinine (4.4, 95% CI 0.9 – 7.8 232 
mmol/L; p=0.02) and urate (0.03, 95% CI 0.001 – 0.04 mmol/L; p=0.003) in the quadpill compared to the 233 
placebo treatment periods,  but no patient had more than a 12% increase in either variable. There were 234 
no significant differences in ALT, AST, sodium, potassium, total cholesterol or LDL-cholesterol. (Appendix 235 
table 3) 236 
The results of the systematic review together with the office BP reduction in the quadpill trial are 237 
summarised in Figure 2. 238 
Discussion 239 
 240 
This study found that a capsule containing four quarter-dose BP lowering drugs reduced 24-hour 241 
ambulatory BP by 19/14mmHg and achieved office BP <140/90mmHg in all participants. This BP 242 
lowering effect is consistent with the findings of our systematic review that single quarter-dose therapy 243 
produces a 5/2mmHg BP reduction against placebo and that dual quarter-dose therapy produces 244 
additional effects on BP.8  Together with findings from our systematic review that single or dual quarter-245 
dose therapy produces no increase in side effects compared to placebo, these findings indicate 246 
considerable potential advantages for a single capsule containing multiple BP lowering drugs in ultra-low 247 
dose.  248 
There has been one prior trial of quadruple quarter-dose BP-lowering versus monotherapy, involving 249 
110 untreated individuals with BP >140/90mmHg.15 That trial observed a 26/15mmHg reduction in BP 250 
from a baseline of 160/96mmHg with therapy comprising amlodipine 1.25mg, atenolol 12.5mg, 251 
bendroflumethiazide 0.625mg and captopril 50mg, which was significantly greater than the reduction 252 
seen with each monotherapy at standard dose - compared with individual agents, the combination 253 
showed a greater systolic BP reduction than amlodipine (8 mmHg, 95% CI 1 to 14mmHg), atenolol (9, 2 254 
to 16 mmHg), bendroflumethiazide (11, 4 to 18mmHg) and captopril (7, 1 to 14mmHg). The only other 255 
trial to date of low-dose antihypertensive therapy with more than two agents assessed triple half-dose 256 
therapy vs. placebo in a crossover trial and demonstrated a similarly large BP difference of 18/10mmHg 257 
(p<0.001).16  258 
The main limitations of this trial is the small sample size and short follow-up duration and the minimal 259 
power it had to evaluate side effects. A major barrier to recruitment was identifying untreated 260 
individuals with elevated BP within the settings in which we work. The systematic review findings and 261 
previous related trials15,16 suggest consistency in effect sizes and supports the minimal side effects 262 
observed. The strengths of this study include the randomised cross-over design maximising statistical 263 
power and minimising bias.  264 
Small but statistically significant increases in creatinine and urate were observed in this trial, with no 265 
patient experiencing more than a 12% increase in either measure. There were no longer term follow-up 266 
data and any clinical implications are uncertain. Lower systemic pressure can reduce glomerular 267 
perfusion pressure and lead to longer term renal benefits for people with raised intraglomerular 268 
pressure and proteinuria.17,18 19,20 However, trials have also observed an increase in adverse renal 269 
outcomes with intensive BP lowering.7,21,22 To determine the clinical implications of the creatinine 270 
differences observed in this study,  studies with further long-term data are required. 271 
Sub-optimal BP control is a global problem.4,23  Initiating treatment with dual combination therapy has 272 
been advocated24 as a more effective means to achieve BP control rapidly and with fewer clinical visits.25 273 
Our study draws on the same underlying principles but extends the concept further to initiating 274 
treatment with multiple ultra-low dose agents in a single capsule.26 In comparison to existing 275 
approaches to BP lowering therapy, administration of a single quadruple combination capsule is likely to 276 
achieve more BP lowering than up-titrating monotherapy, since doubling the dose for BP drugs from 277 
half-dose to full dose provides only about 1-2mmHg further reduction in BP.8 In addition a quadpill 278 
approach could address physician and patient-related treatment inertia as it reduces the need for 279 
stepped titration. It also addresses the individual variation in responsiveness to different agents through 280 
provision of a combination with a range of modes of action. Improved adherence is also likely as a result 281 
of both decreased pill burden27 and use of lower doses to minimise side effects.8   282 
In summary, this is the first placebo-controlled trial demonstrating that quarter-dose quadruple 283 
combination therapy is highly efficacious in lowering BP. It presents a novel approach that could achieve 284 
substantially greater BP control with a single pill, which may have wide-spread clinical applicability.  285 
Further trials are required to assess the long-term efficacy and safety in a broader population, both for 286 
initial treatment and among patients with inadequate control and/or side effects while receiving 287 
monotherapy.  288 
289 
Panel: Research in context  290 
Evidence before this study  291 
Systematic review and meta-analysis of 354 randomised double-blind placebo-controlled trials of BP 292 
lowering therapy8 identified that doubling of dose from half to full standard dose produced on average a 293 
22% increase in BP reduction, and that the BP lowering effect of different classes of drugs were additive. 294 
While most benefits are maintained at half-dose, most side effects were avoided. One trial 295 
demonstrated a quadruple quarter-dose therapy achieved greater BP reduction than each component at 296 
standard dose.15 297 
Added value of this study  298 
We systematically reviewed the literature on placebo controlled quarter-dose BP-lowering therapy and 299 
found placebo-corrected BP reductions with single and dual quarter-dose BP lowering of 5/2mmHg and 300 
7/5mmHg respectively. These reductions were not associated with any difference in side effects 301 
compared to placebo. Our trial provides the first placebo-controlled data on a four agent quarter-dose 302 
‘quadpill’ containing irbesartan 37.5mg, amlodipine 1.25mg, hydrochlorothiazide 6.25mg and atenolol 303 
12.5mg, combined into a single capsule).  We observed a BP reduction of 19/14 mmHg in 24 hour SBP 304 
compared to placebo, and 18/18 patients achieved BP <140/90mmHg while receiving Quadpill 305 
compared to 6/8 while receiving placebo (p<0.001). 306 
Implications of all the available evidence  307 
This study provides proof of concept for an innovative approach of using ultra-low-dose quadruple 308 
combination therapy to achieve substantial BP reductions. Further studies are required to examine the 309 
generalisability of these findings and assess the longer term effects on efficacy, safety and tolerability 310 
compared to usual care.  311 
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 Table 1 Baseline characteristics of trial participants 
Characteristics  
Mean age, years (SD)  58 (11) 
24-hour SBP/ DBP (mmHg)  140 (9)/ 87 (8) 
Office BP (mmHg)  154 (14) / 90 (11) 
Mean months since diagnosis of hypertension (SD)  4.2 (5.4) 
Female, n (%)  11 (52%) 
University education   9 (43%) 
Diabetes  2 (10%) 
Hyperlipidaemia  5 (24%) 
Previous myocardial infarction  0 (0%) 
Coronary artery revascularisation  0 (0%) 
Cerebrovascular disease  0 (0%) 
Previous depression  4 (19%) 
Current smoker  5 (46%) 
 
SD: standard deviation; SBP: systolic blood pressure; DBP: diastolic blood pressure; BP: blood pressure 
 
Table 2 Effects of quadpill and placebo on blood pressure parameters  
 Quadpill treatment period  Placebo treatment period    
Parameter 
Baseline  
(week 0 or week 6) 
End of treatment 
(week 4 or week 10)  
Baseline  
(week 0 or week 6) 
End of treatment 
(week 4 or week 10)   
Difference in change between Quadpill 
and Placebo period in mmHg (95% CI) * p-value * 
 
Mean BP levels (mmHg)        
Mean 24hr SBP 138.4  119.6   137.1  138.2   -18.7 (-23.2; -14.2) <0.0001 
Daytime ASBP 141.7 121.4   140.3  143.7  -22.3 (-26.9; -17.7) <.0001 
Daytime ADBP 89.9 75.7   87.9  91.1  -15.3 (-18.1; -12.6) <.0001 
Night-time ASBP 128.8 114.4   126.2  125.4  -10.4 (-18.3; -2.6) 0.0128 
Night-time ADBP 77.7 66.8   77.8  79.4  -12.5 (-17.1; -7.9) <.0001 
Mean 24hr DBP 86.7 73.3   85.1  87.6  -14.2 (-16.9; -11.5) <.0001 
Office SBP 149.9 122.1   145.8  144.6  -22.4 (-28.3; -16.5) <.0001 
Office DBP 87.4 71.8   86.1  84.8  -13.1 (-17.3; -8.8) <.0001 
BP: blood pressure; SBP: systolic blood pressure; ASBP: ambulatory systolic blood pressure; ADBP: ambulatory diastolic blood pressure; DBP diastolic blood 
pressure; ABP: ambulatory blood pressure; CI: confidence interval; N/A: not applicable 
 
Table 3  – Adverse events 
Event 
Study drug allocated 
when occurred 
Treatment period 
when occurred Severity Action Taken Outcome Relationship 
Gastro Illness Quadpill 1st  Mild None Resolved Not Related 
Headache Quadpill 1st  Mild None Resolved Not Related 
Dry Nose Placebo 2nd  Mild None Resolved Not Related 
Vertigo Neither Between 1st & 2nd   Mild None Resolved Not Related 
Dizziness Quadpill 1st Mild Temporarily discontinued study drug Resolved Related 
Urinary Frequency* Quadpill 1st  Mild None Resolved Possibly Related 
Urinary Frequency* Placebo 2nd  Mild None Resolved Possibly Related 
Respiratory Tract Infection Quadpill 2nd  Mild None Resolved Not Related 
* Urine Frequency was reported by one male patient during the intervention phase and same patient in the placebo phase. He was instructed to 
consult local doctor for urologic assessment.  
 
 Figure 1 Study design for randomised trial 
 
*quadpill = irbesartan 37.5mg, amlodipine 1.25mg, hydrochlorothiazide 6.25mg, atenolol 
12.5mg; BP: blood pressure 
 
Patients with untreated high blood pressure  
(2 office BP measures on 2 different days >140/90mmHg) 
Randomise 
Quadpill* Week 0 - 4 
Week 6 - 10 
Final visit (week 10): 24-hr BP, bloods, adverse events, acceptability questionnaire 
Baseline visit (week 0) 
Clinical questionnaire, 24-hour ambulatory BP, bloods 
 Visit 2 (week 4): 24-hr BP, bloods, adverse events  
 Visit 3 (week 6): 24-hr BP 
Week 4 - 6 
Placebo 
2-week washout 2-week washout 
Quadpill* Placebo 
Figure 2 Efficacy of single, dual and quadruple quarter-dose therapy on blood pressure lowering, compared to placebo 
 
 
Data on single quarter and dual quarter dose are from the systematic review. Data on quadruple quarter dose is from the Quadpill trial 
described in this paper. 
Figure 3  Study flow diagram 
 
Patients Screened
N = 55
Patients in trial
N = 20
Participant withdrawal 
After 4 weeks = 2
Participants completing 10 
week
N = 18
Not randomised N = 34
Medically ineligible N=11
Too busy / Declined participation N = 10
White coat hypertension = 5
Not contactable = 9
21 Patients eligible for randomisation. 
1 patient declined study drug initiation.
Appendix  
Appendix 1: Medline Search and eligible trials  
1. Hypertension/ or hypertension.mp. 
2. high blood pressure.mp. or Hypertension/ 
3. resistant hypertension.mp. 
4. severe hypertension.mp. 
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9. raised blood pressure.mp. 
10. elevated blood pressure.mp. 
11. hypertensive.mp. 
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18. very low dose combination$.mp. 
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20. Dose-Response Relationship, Drug/ or dose response relationship$.mp. 
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37. controlled clinical trial.pt. 
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40. drug therapy.fs. 
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42. trial.ab. 
43. groups.ab. 
44. exp animals/ not humans.sh. 
45. Randomized controlled trial.pt. 
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47. 46 not 44 
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Web table 1. Baseline characteristics of included trials 
Trial Origin Design Study treatments 
Sample 
size [n, 
ITT] 
Mean 
age 
(yrs) 
% 
female 
Disease 
criteria 
BP measure 
BP eligibility 
(mmHg) 
Mean 
baseline 
SBP/DBP 
(mmHg) 
Relevant reported 
outcomes 
Interventi
on 
(weeks) 
% lost to 
follow-up 
#866-09, 2001 EU 
double blind, 6 
groups, parallel 
Olmesartan (¼ ½, 
1, 2, 4) vs. placebo  
790 56 - 
Mild-moderate 
essential 
hypertension 
in office, 
sitting 
100<DBP<115 164/NA 
DBP, SBP, treatment 
discontinuation 
12 7% 
#866-10, 1999 EU 
 double blind, 4 
groups, parallel 
Olmesartan (¼ ½, 
1) vs. placebo 
600 59 - - 
in office, 
sitting 
95<DBP<110 164/105 DBP, SBP 12 - 
#866-204 USA 
double blind, 7 
groups, parallel 
Olmesartan (od & 
bid: ¼, 1, 4) vs. 
placebo 
299 - - 
Essential 
hypertension 
in office, 
supine 
100<DBP<115 155/104 
DBP, SBP, treatment 
discontinuation 
8 - 
#866-305, 1999 USA 
double blind, 6 
groups, parallel 
Olmesartan (¼, ½, 
1, 2, 4) vs. placebo 
517 55 - 
Essential 
hypertension 
in office, 
sitting 
100<DBP<115 154/103 DBP, SBP 8 - 
Bergstrand, 
1985 
Swede
n 
double blind, 6 
group, incomplete-
block 
Enalapril (1/8, ¼ 
½, 1, 2) vs. 
placebo 
91 56 37% 
Mild-moderate 
hypertension 
in office, 
sitting 
90<DBP<116 159/97 DBP, SBP 3 0% 
Canter, 1994 USA 
double blind, 4 x 4 
factorial 
HCTZ (¼, ½, 1) 
quinapril (1/8, ½, 
2) vs. placebo 
458 53 37% Hypertension 
in office, 
sitting 
100<DBP<115 162/105 DBP, SBP, potassium 4 0% 
Casadei, 1992 UK 
 double-blind, 
cross-over 
Carvedilol (¼ ½, 1) 
vs. placebo 
20 27 - 
Untreated 
hypertension 
ABP monitor 90<DBP 151/100 DBP, SBP 4 13% 
Chrysant, 1996 USA 
double blind, 
incomplete 4 x 4 
factorial  
Benazepril (¼, ½, 
1) HCTZ (¼, ½, 1) 
vs. placebo 
334 53 37% 
Uncomplicate
d essential 
hypertension 
in office, 
sitting 
95<DBP<115 - 
DBP, SBP, adverse 
events, treatment 
discontinuation, 
potassium  
6 10% 
De Bruijn, 1994 
Netherl
ands 
double blind, 4 
groups, parallel 
Trandolapril (¼ ½, 
1) vs. placebo 
170 - - 
Mild-moderate 
hypertension 
in office, 
supine 
95<DBP<115 161/100 DBP, SBP 4 - 
DeQuattro, 1997 USA 
double blind, 5 x 4 
factorial 
Trandolapril (¼, 1, 
4) verapamil (½, 
3/4, 1) vs. placebo 
726 55 37% 
Stage I-III 
diastolic 
primary 
hypertension 
in office, 
sitting, trough 
95<DBP<114 153/101 
DBP, SBP, adverse 
events 
6 7% 
EC009, 1994 
Germa
ny 
double blind, 5 
group, parallel 
Candesartan (¼ ½, 
1, 2) vs. placebo 
232 - - Hypertension - 95<DBP<114 - 
DBP, SBP, adverse 
events 
4 3% 
EC403, 1996 
Germa
ny 
double blind, 4 x 2 
factorial 
Candesartan (¼, 
½, 1, 2) HCTZ (½, 
1) vs. placebo 
1,038 - - 
Mild-moderate 
hypertension 
- 95<DBP<110 NA/101 
DBP, SBP, treatment 
discontinuation, uric 
acid 
6 - 
Frick, 1988 Finland 
single blind, 
parallel 
Amlodipine (¼, ½, 
1) vs. placebo 
205 50 - 
Mild-moderate 
hypertension 
in office, 
supine 
90<DBP<115 161/102 
DBP, SBP, adverse 
events, treatment 
discontinuation  
4 - 
Frishman, 1994 USA 
double blind, 4 x 3 
factorial 
Bisoprolol (¼, 1, 4) 
HCTZ (¼, 1) vs. 
placebo 
465 53 29% 
Mild-moderate 
essential 
hypertension 
in office, 
sitting 
95<DBP<114 151/101 
DBP, SBP, uric acid, 
potassium 
12 21% 
Frishman, 2006 USA 
double blind, 
unbalanced 4 x 4 
factorial 
Metoprolol (¼, 1, 
4) felodipine (½, 2, 
4) vs. placebo 
1,087 54 43% 
Essential 
hypertension 
in office, 
sitting 
95<DBP<114 153/100 
DBP, SBP, treatment 
discontinuation  
9 17% 
Gomez, 1989 
USA & 
Swede
n 
double blind, 4 
groups, parallel 
Lisinopril (¼, 1, 4) 
vs. placebo 
216 - 10% 
Mild-
moderate, 
uncomplicated 
in office, 
supine 
95<DBP<115 159/101 
DBP, SBP, adverse 
events, treatment 
discontinuation, 
potassium  
6 11% 
essential 
hypertension 
Gradman, 1998 USA 
double blind, 3 x 4, 
factorial 
Enalapril (¼, 1) 
felodipine (½, 1, 2) 
vs. placebo 
705 53 35% 
Essential 
hypertension 
in office, 
sitting 
95<DBP<115 155/102 DBP, SBP 8 9% 
Jounela, 1994 
Scandi
navia 
Double blind, 5 
groups, parallel 
HCTZ (1/8, ¼, ½, 
1) vs. placebo 
111 48 - 
Mild-moderate 
essential 
hypertension 
in office, 
supine 
95<DBP<115 152/99 
DBP, SBP, adverse 
events, mediation 
discontinuation 
6 3% 
Kochar, 1999 USA 
double blind, 4 x 4 
factorial 
Irbesartan (¼, 2/3, 
2) HCTZ (¼, ½, 1) 
vs. placebo 
683 55 15% 
Mild-moderate 
hypertension 
in office, 
sitting 
95<DBP 151/100 DBP, SBP, uric acid 8 8% 
McGill, 2001 USA 
double blind, 4 x 5 
factorial 
HCTZ (¼, ½, 1) 
telmisartan (½, 1, 
2, 4) vs. placebo 
749 53 40% 
Mild-moderate 
hypertension 
in office, 
supine 
140<SBP<200 154/101 
DBP, SBP, 
Potassium 
8 7% 
McMahon, 1989 USA 
double blind, 5 
groups, parallel 
Verapamil (¼, ½, 
1, 2) vs. placebo 
213 55 43% 
Mild-moderate 
essential 
hypertension 
in office, 
supine 
95<DBP<115 156/101 
DBP, SBP, adverse 
events, treatment 
discontinuation 
6 9% 
Mehta, 1993 USA 
double blind, 5 
groups, parallel 
Amlodipine (¼, ½, 
1, 2) vs. placebo 
203 53 46% 
Mild-moderate 
essential 
hypertension 
in office, 
supine 
95<DBP<115 152100 
DBP, SBP, treatment 
discontinuation 
4 3% 
Meineke, 1997 
Germa
ny 
double blind, 6 
groups, parallel 
Candesartan (¼, 
½, 1, 2, 4) vs. 
placebo) 
232 53 56% 
Mild-moderate 
arterial 
hypertension 
in office, 
sitting 
95<DBP<115 150/98 DBP, SBP 4 - 
Mitrovic, 2003 
EU and 
RSA 
double blind, 5 
groups, parallel 
Candesartan (¼, 
½, 1, 2) vs. 
placebo 
218 54 15% 
Heart failure 
(NYHA class II 
or III) 
right heart 
catheter 
- - 
adverse events, 
treatment 
discontinuation, uric 
acid, potassium 
12 - 
Moser, 1991 USA 
double blind, 7 
groups, parallel 
Benazepril (1/10, 
¼, ½, 1) HCTZ (1) 
vs. placebo 
206 50 34% 
Mild-moderate 
hypertension 
in office, 
supine 
95<DBP<115 153/102 
DBP, adverse events, 
treatment 
discontinuation 
4 14% 
NEB-302, 2003 USA 
double blind, 6 
groups, parallel 
Nebivolol (¼, ½, 1, 
2, 4) vs. placebo 
909 55 43% 
Mild-
moderate, 
uncomplicated 
hypertension 
in office, 
sitting, trough 
95<DBP<110 153/100 
SBP, DBP, treatment 
discontinuation 
- - 
Neutel, 1997 USA 
double blind, 6 
groups, parallel 
Valsartan (¼, 1, 2, 
4) vs. placebo 
216 - 25% 
Uncomplicate
d essential 
hypertension 
in office, 
supine 
95<DBP<115 148/91 DBP, SBP 8 0% 
Omboni, 1989 Italy 
double blind, 4 
groups, parallel 
Lercanidipine (¼, 
½, 1) vs. placebo 
243 51 34% 
Mild-moderate 
essential 
hypertension 
in office, 
sitting 
90<DBP<110 155/99 
DBP, SBP, adverse 
events, treatment 
discontinuation 
4 5% 
Oparil, 1996 USA 
double blind, 5 
groups, parallel 
Valsartan (¼, 1, 2, 
4) vs. placebo 
729 53 34% 
Uncomplicate
d essential 
hypertension 
in office, 
supine 
95<DBP<115 151/101 
DBP, SBP, adverse 
events, treatment 
discontinuation 
8 8% 
Papademetriou, 
2006 
USA 
double blind, 5 x 4 
factorial 
Metoprolol (¼, ½, 
1, 2) HCTZ (¼, ½, 
1) vs. placebo 
1559 53 50% Hypertension 
in office, 
sitting 
95<DBP<115    
SBP<180 
151/100 DBP, SBP 10 11% 
Pool, 1997 USA 
double blind, 4 x 4 
factorial 
Fosinopril (¼, 1, 2, 
4) HCTZ ((¼, ½, 
1.5) vs. placebo 
548 52 39% 
Mild-moderate 
essential 
hypertension 
in office, 
sitting 
95<DBP<110 150/100 DBP, SBP 8 - 
Reif, 1996 USA 
double blind, 6 
groups, parallel 
Candesartan (¼, 
½, 1, 2, 4) vs. 
placebo 
360 55 34% 
Systemic 
hypertension 
in office, 
sitting, trough 
95<DBP<115 153/100 
DBP, SBP, adverse 
events, treatment 
discontinuation 
8 9% 
Roca-Cusachs, 
2001 
Spain 
double blind, 4 x 4 
factorial 
Enalapril (¼, ½, 1) 
nitrendipine 
(¼, ½, 1) vs. 
placebo 
378 56 60% 
Mild-moderate 
essential 
hypertension 
in office, 
sitting 
90<DBP<110 158/99 DBP, SBP 6 9% 
Schoenberger, 
1989 
USA 
double blind, 4 
groups, parallel 
Penbutolol (¼, ½, 
1) vs. placebo 
302 51 47% 
Systemic 
hypertension 
in office, 
supine 
95<DBP<115 152/100 
DBP, SBP, adverse 
events 
6 12% 
Sedman, 1989 USA 
double blind, 4 
groups, parallel 
Quinapril (¼, ½, 1) 
vs. placebo 
247 - - 
Uncomplicate
d mild 
hypertension 
in office, 
sitting, trough 
95<DBP<115 156/103 DBP, SBP 6 8% 
Study 01-05, 
2006 
USA, 
SA 
double blind, 5 
groups, parallel 
Azilsartan (¼, ½, 
1, 2) olmesartan 
(1) vs. placebo 
404 - - 
Mild-
moderate, 
uncomplicated 
hypertension 
in office, 
sitting 
95<DBP<115 151/100 
DBP, SBP, adverse 
events 
8 10% 
Thakkar, 2016 AUS 
Double blind, 2 
groups, crossover 
Amlodipine (¼), 
atenolol (¼), HCTZ 
(¼), irbesartan (¼) 
vs. placebo  
20 58 52% Hypertension 
In office, 
sitting 
90<DBP or 
140<SBP 
148/87 
DBP, SBP, adverse 
events, treatment 
discontinuation, 
potassium, uric acid 
4 10% 
Villamil, 2007 USA 
Double blind, 
factorial 4 x 4 
factorial 
Aliskiren (½,1, 2) 
HCTZ (¼, ½, 1) vs. 
placebo  
2,752 55 45% 
Mild-moderate 
hypertension 
in office, 
sitting, trough 
95<DBP<110 153/99 
DBP, SBP, Adverse 
events, treatment 
discontinuation 
8 - 
Williams, 1992 USA 
double blind, 4 
groups, parallel 
Betaxolol (¼, ½, 1) 
vs. placebo 
317 - 38% 
Mild-moderate 
hypertension 
in office, 
supine 
95<DBP 150/100 
DBP, SBP, treatment 
discontinuation 
4 9% 
 
  
Web Table 2 Effects on 24-hour mean SBP, by treatment period and sequence allocation (mmHg) 
 Treatment period  
Treatment sequence 1 2 
Within-individual difference: 
Quadpill - Placebo 
Quadpill then Placebo    
 Mean (SD) -21.1 (6.8) 5.3 (6.6) -26.7 (9.2) 
 Sample size 10 9 9 
Placebo then Quadpill    
 Mean (SD) -3.0 (17.9) -16.4 (7.5) -13.4 (22.9) 
 Sample size 9 9 9 
Treatment effect    
 Mean (SD)   -18.7 (2.1) & (95% CI-23.0; -14.3) 
 p-value   <.0001 
 Sample size   19 
 
  
 Web Table 3 – Biochemical changes 
 
Difference of changes in quadpill treatment period 
versus placebo treatment period (95% CI) p-value * 
Creatinine (µmol/L) 4.4 (0.9; 7.8) 0.017 
ALT (µmol/L) 3.1 (-4.3; 10.5) 0.38 
AST (µmol/L) -7.3 (-24.1; 9.5) 0.37 
Sodium (mmol/L) -0.6 (-1.8; 0.6) 0.32 
Potassium (mmol/L) -0.04 (-0.2; 0.1) 0.62 
Urate (mmol/L) 0.03 (0.01; 0.04) 0.003 
Total Cholesterol 0.2 (-0.2; 0.6) 0.27 
LDL Cholesterol (mmol/L) 0.2 (-0.2; 0.5) 0.31 
 
 
 Web Figure 1  PRISMA Flow Diagram 
 
 
 
 
 
 
 
 
 
 
 
 
16 full text articles excluded: 
2= duplicate 
2= review 
4= wrong dose 
1= up-titration 
1= not approved drug 
4= under two weeks 
1= no BP measure 
1= full text unavailable 
 
1496 records excluded 
1,712 records identified 
through database searching 
19 records identified through 
other sources 
 
1,554 records after duplicates 
were removed 
1,554 records screened 
58 full text articles 
assessed for eligibility 
42 studies included  
 
36 trials with data on 
quarter dose versus 
placebo 
Identification 
Eligibility 
Included 
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